Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Asset Writedowns and Impairment (2019 - 2024)

Ani Pharmaceuticals (ANIP) has disclosed Asset Writedowns and Impairment for 6 consecutive years, with $7.6 million as the latest value for Q4 2024.

  • Quarterly Asset Writedowns and Impairment changed N/A to $7.6 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $767000.0 for FY2025, 89.91% down from the prior year.
  • Asset Writedowns and Impairment hit $7.6 million in Q4 2024 for Ani Pharmaceuticals, up from -$1000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $7.6 million in Q4 2024 to a low of -$1000.0 in Q3 2022.
  • Historically, Asset Writedowns and Impairment has averaged $2.1 million across 4 years, with a median of $341000.0 in 2020.
  • Biggest five-year swings in Asset Writedowns and Impairment: surged 354.67% in 2020 and later surged 596.19% in 2021.
  • Year by year, Asset Writedowns and Impairment stood at $341000.0 in 2020, then soared by 596.19% to $2.4 million in 2021, then plummeted by 100.04% to -$1000.0 in 2022, then soared by 760100.0% to $7.6 million in 2024.
  • Business Quant data shows Asset Writedowns and Impairment for ANIP at $7.6 million in Q4 2024, -$1000.0 in Q3 2022, and $2.4 million in Q4 2021.